Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of MK-1045 plus rituximab versus physician's choice chemoimmunotherapy in untreated follicular lymphoma
MOH_2026-04-26_015788Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CN201 and rituximab in follicular lymphoma (FL) (6 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
CN201rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2026-04-26_015788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-26_015788.